Mounjaro or Zepbound Denied by Insurance? Appeal Guide

Tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for chronic obesity — represents a genuine therapeutic breakthrough. Yet insurance denials for both versions are common and often unfair. The SURMOUNT clinical trial demonstrated 22.5% mean body weight reduction at 72 weeks — no previously approved medication achieved this level of efficacy. The SURPASS program demonstrated superior A1C reduction compared to every diabetes comparator tested. When an insurer denies tirzepatide, they are often denying a medication with stronger evidence than what they cover instead. Here is how to build a winning appeal.

Why Insurers Deny Mounjaro and Zepbound

The denial patterns for tirzepatide fall into several categories, each requiring a targeted counter-argument:

• "Not medically necessary" — Insurer's reviewer does not believe tirzepatide meets their internal criteria, despite strong clinical trial evidence
• Lifestyle modification required first (step therapy) — Insurer requires documented failure of supervised diet and exercise before approving pharmacotherapy
• Formulary exclusion for "weight loss drugs" — Many employer-sponsored plans use blanket exclusions that may improperly apply to Mounjaro prescribed for type 2 diabetes
• Step therapy through older, less effective medications — Insurer requires metformin failure (diabetes) or phentermine/orlistat failure (weight loss) before approving tirzepatide
• Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization documentation missing — Administrative denial due to incomplete PA submission rather than clinical disagreement
• Off-label prescribing — Mounjaro prescribed for weight loss rather than diabetes when the patient lacks a type 2 diabetes diagnosis; Zepbound is the FDA-approved indication for obesity

How to Appeal a Tirzepatide Insurance Denial

Step 1: Confirm the Correct Indication and Diagnosis Code

The most fundamental step in a tirzepatide appeal is confirming that the diagnosis code on the prior authorization request matches the approved indication. Mounjaro is FDA-approved for type 2 diabetes (ICD-10: E11.x); Zepbound is FDA-approved for chronic obesity (ICD-10: E66.01 morbid obesity; E66.09 other obesity). If the diagnosis code is mismatched to the drug, correct it before appealing. If your prescriber believes both diagnoses apply, discuss which is the primary indication for treatment.

Step 2: Request the Insurer's Clinical Coverage Policy for Tirzepatide

Under 29 CFR § 2560.503-1 (ERISA plans) and 45 CFR § 147.136 (ACA plans), you have the right to the specific criteria your insurer applied. Request this document immediately. Read each criterion and determine which ones you clearly satisfy and which ones the insurer claims you do not. Your appeal will address each criterion specifically.

Step 3: Build Your Clinical Evidence Package

Your physician's letter of medical necessity is the foundation of your appeal. For Mounjaro (diabetes appeals): document A1C levels (typically ≥7.0% despite current therapy), medications already tried with dates, dosages, and outcomes, reasons any required step therapy medications are inadequate or contraindicated, and citations to ADA Standards of Care 2024 supporting GIP/GLP-1 agonists. For Zepbound (obesity appeals): document BMI (≥30 or ≥27 with comorbidity), weight-related comorbidities (hypertension, sleep apnea, type 2 diabetes, NAFLD, cardiovascular disease), documented lifestyle intervention attempts, and citations to SURMOUNT-1 (NEJM, 2022) demonstrating 22.5% mean weight loss — three times the efficacy of older agents.

Step 4: Counter Step Therapy Requirements with Specific Clinical Evidence

If the insurer requires you to fail specific prior therapies, provide: dates, doses, and clinical outcomes for each required medication you have already tried; your physician's letter explaining why each required step therapy medication is inadequate or contraindicated for you; and physiological evidence for why pharmacotherapy is appropriate even without prior program failure (citing Sumithran et al., NEJM 2011: hormonal compensatory mechanisms after weight loss are persistent and physiological, not a failure of willpower). If you live in one of the 20+ states with step therapy reform laws, cite the specific statute in your appeal.

Step 5: Write and Submit Your Appeal Letter

Your appeal letter should quote the insurer's exact denial language and address each stated criterion point by point. For Zepbound appeals, include this sample language: "The requested medication, tirzepatide (Zepbound), is FDA-approved for chronic obesity (ICD-10: E66.01) in adults with BMI ≥ 30 kg/m². SURMOUNT-1 demonstrated 22.5% mean body weight reduction — a magnitude of effect not achievable with any other FDA-approved pharmacotherapy currently available. Denial of this drug in favor of less effective alternatives contradicts guidelines from the American Diabetes Association, Obesity Medicine Association, and American College of Cardiology." Submit via certified mail and the insurer's member portal simultaneously.

Step 6: Request Peer-to-Peer Review and External Independent Review: Complete Guide" class="auto-link">External Review

Request that your prescribing physician speak directly with the insurer's medical reviewer. Tirzepatide peer-to-peer reviews reverse many denials when the prescriber can explain the specific clinical superiority of tirzepatide over required step-through alternatives. If the internal appeal fails, file for external review — mandated under ACA Section 2719 for all non-grandfathered plans. The SURMOUNT and SURPASS trial data provide strong evidence that external reviewers can rely upon.

What to Include in Your Appeal

• Your denial letter with the specific reason and criteria cited by the insurer
• Your physician's letter of medical necessity addressing each of the insurer's stated criteria
• Lab results: A1C levels and trend (diabetes), BMI documentation and comorbidity labs (obesity)
• Documentation of prior medications tried with dates, dosages, and clinical outcomes
• SURMOUNT-1 trial citation (Zepbound) or SURPASS trial citations (Mounjaro) from the NEJM
• ADA Standards of Care 2024 and/or Obesity Medicine Association guidelines
• Step therapy reform statute citation if applicable in your state

Fight Back With ClaimBack

Tirzepatide denials are among the most reversible in current insurance practice — the clinical evidence from SURMOUNT and SURPASS is overwhelming, and insurers' internal criteria frequently do not hold up to external scrutiny. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal